Skip to main content

Table 1 Patients' demographic and baseline disease characteristics

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

  Number of patients (%)
Patients' characteristics DD/DI arm (N = 86) HDI arm (N = 80)
Age, years     
Mean (SD) 47 (13)   52 (13)  
Gender     
Male 47 (55) 54 (67)
Female 39 (45) 26 (33)
ECOG Performance Status     
0 81 (94) 76 (95)
1 5 (6) 4 (5)
Site of primary tumor     
Head/neck 3 (3) 6 (7)
Trunk 50 (58) 40 (50)
Upper limb 7 (8) 6 (8)
Lower limb 26 (30) 24 (30)
Unknown 0 (0) 4 (5)
Ulceration     
No 45 (52) 36 (45)
Yes 33 (39) 34 (43)
Unknown 8 (9) 10 (12)
Breslow's thickness (mm)     
1 2 (2) 7 (9)
1.01 – 2.0 27 (31) 18 (23)
2.01 – 4.0 30 (35) 29 (36)
>4 22 (26) 17 (21)
Unknown 5 (6) 9 (11)
Nodal classification     
N0 0 (0) 2 (2)
N1 56 (65) 46 (58)
N2 19 (22) 24 (30)
N3 11 (13) 8 (10)